3D Ex Vivo Tumor Models for Predicting TTFields Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating glioblastoma with Tumor Treating Fields (TTFields) face challenges in predicting patient response due to the difficulty in acquiring matched treatment-naïve and recurrent patient tissues, limiting the understanding of molecular effects and resistance mechanisms in humans.
Innovation Solution
The development of three reliable patient-derived 3-dimensional ex vivo models, including microtumors, organoids, and tumor slice cultures, which allow for the application of alternating electric fields to determine efficacy and identify biomarkers responsive to TTFields treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If matched treatment-naïve and recurrent patient tissues are acquired for studying TTFields effects, then molecular effects and resistance mechanisms can be investigated, but acquisition difficulty limits the availability of such tissues
Solution Approach 1:
The patent creates ex vivo 3D tumor models that copy the structural and functional characteristics of patient-derived tumors. These models include tumor spheroids, organoids, and patient-derived xenografts that replicate tumor architecture, cell-cell interactions, and molecular profiles, enabling reliable TTFields response prediction without requiring direct access to matched patient tissues at multiple time points
Solution Approach 2:
The patent establishes ex vivo tumor models in advance before treatment initiation. These pre-established models allow researchers to study baseline tumor characteristics and predict treatment response before patients receive TTFields therapy, eliminating the need to acquire and process matched treatment-naïve and recurrent tissues separately
2Loss of information
If ex vivo 3D models are used to predict treatment response, then patient response prediction and molecular insights are improved, but model complexity and development requirements increase
Solution Approach 1:
The patent segments the complex task of tumor modeling into distinct approaches: 2D monolayer cultures for basic molecular studies, 3D tumor spheroids for architectural insights, organoids for physiological relevance, and patient-derived xenografts for comprehensive in vivo modeling. Each segment addresses specific research questions while maintaining manageable complexity
Solution Approach 2:
The patent transitions from traditional 2D cell culture models to 3D ex vivo models, adding a spatial dimension that recapitulates tumor architecture, cell-cell interactions, and microenvironmental cues. This dimensional change preserves molecular and cellular information that is lost in planar cultures while maintaining experimental tractability
3Manufacturing precision
If multiple frequencies of alternating electric field are applied to determine optimal treatment, then treatment efficacy is optimized, but testing time and resource requirements increase
Solution Approach 1:
The patent applies a range of frequencies exceeding the clinical standard (e.g., testing 50-500 kHz beyond the typical 100-200 kHz range) to identify optimal frequencies for specific tumor types and models. This excessive action ensures comprehensive optimization while the ex vivo model format accelerates the process compared to clinical trial timelines
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These models enable the prediction of patient treatment response and provide insights into clinically relevant cellular and molecular alterations, optimizing TTFields therapy by identifying effective frequencies and potential biomarkers for personalized treatment.
Implementation Method 1
These alternating electric fields are applied to glioblastoma at 200 kHz frequency via arrays placed on the shaved scalp of patients
Data Source
AI summary
Disclosed are methods of determining the efficacy of an alternating electric field comprising applying an alternating electric field to one or more microtumors for a period of time, the alternating electric field having a frequency and field strength, wherein the microtumor comprises primary cancer cells; and determining the efficacy of the alternating electric field. Disclosed are methods of testing the efficacy of an alternating electric field comprising applying alternating electric fields to one or more organoids for a period of time, the alternating electric fields having a frequency and field strength, wherein the organoids are cultured on organotypic hippocampal slice cultures; and determining the efficacy of alternating electric fields. Disclosed are methods of testing the efficacy of alternating electric fields on a subject comprising culturing or incubating one or more tumor slices from the subject, applying alternating electric fields to the one or more tumor slices for a period of time, the alternating electric fields having a frequency and field strength, and determining the efficacy of alternating electric fields.